Melanoma-associated antigen E1 (MAGEE1)

Melanoma-associated antigen E1 (MAGEE1) is a member of the MAGE protein family, encoded on the X chromosome. It contains two MAGE domains in the C-terminus and is associated with alpha-dystrobrevin, potentially modulating cellular signaling in brain, muscle, and peripheral nerve. MAGEE1 may act to enhance ubiquitin ligase activity, especially RING-type E3 ubiquitin ligases, by recruiting and stabilizing ubiquitin-conjugating enzymes at the E3:substrate complex. It is linked to tumor biology, with overexpression in melanoma and other cancers; potential as a tumor-associated antigen renders it a candidate for immunotherapy, although no approved drugs target it directly to date[1][2][5]. Its function extends to possible transcriptional regulation and modulation of cell proliferation and differentiation. High expression levels may serve as a prognostic biomarker for certain cancers. Safety and therapeutic challenges are similar to other MAGE family antigens, predominantly revolving around immune specificity and tumor heterogeneity.

Other names

HCA1KIAA1587DAMAGEAlpha-dystrobrevin-associated MAGE proteinHepatocellular carcinoma-associated protein 1MAGE-E1 antigenDystrobrevin-associated MAGE proteinMelanoma antigen family E, 1Melanoma antigen family E1

For drug targeting, most reported mechanisms are immunotherapeutic strategies where the antigen is presented for recognition by T-cells (cancer vaccines, adoptive cell therapy). If involved indirectly, mechanism relates to modulation of ubiquitin ligase pathways affecting protein turnover.